DUBLIN–(BUSINESS WIRE)–The “Global
Antidiuretic Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s
offering.
The antidiuretic drugs market will register a CAGR of almost 10% by 2023.
With the rapid onset of modernization, the lifestyle of people is also
changing. The prevalence of such health conditions is rising globally
due to the sedentary lifestyle. Furthermore, the high prevalence of
conditions such as urinary incontinence and interstitial cystitis has
been substantially contributing to the global antidiuretic drugs market.
According to the CDC, the prevalence of nocturia in the US during
2013-2014 was found to be nearly 25% of the population. and the
prevalence rate increased to about 40% in the people affected with
chronic kidney diseases. Such a high prevalence of chronic conditions
leads to polyuria and nocturia, which, in turn, will help in driving the
global antidiuretic drugs market.
Rising geriatric population
The prevalence of chronic conditions that lead to various urologic
diseases, including polyuria and nocturia, increases with age, and these
conditions are prevalent in the geriatric population.
Furthermore, rapid developments in the healthcare facilities and
advanced treatment options have increased the life expectancy of the
geriatric population globally. Rising awareness about various health
conditions has been substantially contributing to the higher life
expectancy.
Stringent regulator policies
One of the major challenges faced by the pharmaceutical vendors is the
stringent policies set by various regulatory bodies and governing
authorities globally.
The US FDA has increased the regulatory surveillance for the drugs
treating rare diseases, to avoid any associated risks. Hence, the
disappointing results in drugs performance lead to the postponement of
marketing approvals, which, further hampers the market growth.
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY APPLICATION
- Comparison by application
- Autoimmune diseases – Market size and forecast 2018-2023
- Urologic diseases – Market size and forecast 2018-2023
- Other applications – Market size and forecast 2018-2023
- Market opportunity by application
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic comparison
- North America – Market size and forecast 2018-2023
- Europe – Market size and forecast 2018-2023
- Asia – Market size and forecast 2018-2023
- RoW – Market size and forecast 2018-2023
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Avadel
- CSL Limited
- Ferring B.V.
- Novartis AG
- Sanofi
For more information about this report visit https://www.researchandmarkets.com/r/sbps2
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs